Gujarat Fluorochemicals
- P/E
- 83.76
Key Fundamentals
MidcapChemicals & PetrochemicalsChemicalsPrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- 9.64%
- Debt to Equity
- 0.35
- EPS (TTM)
- ₹55.08
- Book Value
- ₹763.95
- Market Cap
- —
- P/E (TTM)
- 83.76
- P/B
- 6.04
- ROE
- 7.82%
- Dividend Yield
- 0.07%
- EBITDA
- ₹1,332 Cr
- 52W High
- ₹4,958.90
- 52W Low
- ₹2,916.60
- Volume
- 0
Peer Comparison
Commodities › Chemicals › Specialty Chemicals
| ₹1,510.20 | 58.04 | ₹1,54,107 Cr | 13.72 | 1.42% | 23.90% | 31.00% | ₹15,399 Cr | ₹2,677 Cr | |
| ₹4,613.30 | 83.76 | ₹49,073 Cr | 6.04 | 0.07% | 7.82% | 9.64% | ₹5,303 Cr | ₹600 Cr | |
| ₹8,785.00 | 57.03 | ₹44,060 Cr | 10.10 | 0.09% | 19.60% | 21.00% | ₹3,634 Cr | ₹789 Cr | |
| ₹1,578.40 | 27.48 | ₹20,919 Cr | 3.32 | 0.49% | 9.82% | 11.40% | ₹8,575 Cr | ₹784 Cr | |
| ₹1,540.70 | 86.90 | ₹20,030 Cr | 7.88 | 0.00% | 9.66% | 11.90% | ₹1,231 Cr | ₹235 Cr | |
| ₹447.55 | 30.57 | ₹15,838 Cr | 2.59 | 0.23% | 7.13% | 6.86% | ₹9,010 Cr | ₹531 Cr | |
| ₹5,156.50 | 19.67 | ₹14,827 Cr | 2.31 | 0.59% | 11.50% | 14.90% | ₹6,969 Cr | ₹788 Cr | |
| Median 7 companies | ₹1,578.40 | 57.03 | ₹20,919 Cr | 6.04 | 0.23% | 9.82% | 11.90% | ₹6,969 Cr | ₹784 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 52
- Average
- Returns, margins, earnings quality 22% weight
- Valuation
- 23
- Poor
- Cheap vs sector & own history 24% weight
- Growth
- 37
- Poor
- Sales & profit trajectory 9% weight
- Financial Health
- 55
- Average
- Solvency, leverage, coverage 9% weight
- Momentum
- 88
- Strong
- Trend strength, vol-adjusted 12% weight
- Ownership
- 52
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
No strengths listed
Weaknesses
4- Stock is trading at 6.25 times its book value
- Company has a low return on equity of 7.94% over last 3 years.
- Company might be capitalizing the interest cost
- Dividend payout has been low at 6.44% of profits over last 3 years
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bullish | 2 | 5 | 12 |
| Oscillators | Neutral | 2 | 5 | 2 |
| Moving Averages | Strong Bullish | 0 | 0 | 10 |
Oscillators
Neutral
Overall
Strong Bullish
Moving Averages
Strong Bullish
Key readings
- RSI (14)
- 60.59
- Neutral
- MACD (12,26,9)
- −28.95
- Bullish
- SMA (50)
- 4,514.82
- Bullish
- SMA (200)
- 3,887.88
- Bullish
As of
Analyst Rating
10 of 15 analysts rate Buy, 2 Hold, 3 Sell.
As of
Growth Rate
From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.
Revenue
| 5Y | +13.52% |
|---|---|
| 3Y | −4.22% |
| 1Y | +5.47% |
| TTM | +9.52% |
Net profit
| 5Y | Turned to profit |
|---|---|
| 3Y | −24.30% |
| 1Y | +5.13% |
| TTM | −3.23% |
Operating cash flow
| 5Y | +9.30% |
|---|---|
| 3Y | +9.15% |
| 1Y | +76.33% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 5Y | +1.47 pp |
|---|---|
| 3Y | −10.52 pp |
| 1Y | +0.82 pp |
| TTM | +0.28 pp |
Revenue by year
| Mar 2018 | ₹3,851 Cr |
|---|---|
| Mar 2019 | ₹2,729 Cr |
| Mar 2020 | ₹2,606 Cr |
| Mar 2021 | ₹2,650 Cr |
| Mar 2022 | ₹3,954 Cr |
| Mar 2023 | ₹5,685 Cr |
| Mar 2024 | ₹4,281 Cr |
| Mar 2025 | ₹4,737 Cr |
| Mar 2026 | ₹4,996 Cr |
Net profit by year
| Mar 2018 | ₹240 Cr |
|---|---|
| Mar 2019 | ₹1,246 Cr |
| Mar 2020 | ₹189 Cr |
| Mar 2021 | −₹222 Cr |
| Mar 2022 | ₹776 Cr |
| Mar 2023 | ₹1,323 Cr |
| Mar 2024 | ₹435 Cr |
| Mar 2025 | ₹546 Cr |
| Mar 2026 | ₹574 Cr |
Analyst Forecasts
AI Analysis — Bull vs Bear
Gujarat Fluorochemicals Ltd trades at ₹4,463.9 as of 2026-11-03 with a market cap of ₹49,385 crore. The stock commands a premium valuation at 81.04x trailing earnings and 6.27x book value, while return on equity stands at 7.25% and debt-to-equity is a modest 0.35. Compounded profit has declined 24% over three years, though the stock itself has delivered a 17% CAGR over one, three, and five-year horizons.
- Consistent stock price CAGR of 17% across 1-year, 3-year and 5-year periods, indicating sustained investor confidence and steady wealth creation
- Comfortable balance sheet with a debt-to-equity ratio of just 0.35, providing financial flexibility for future capacity expansion or new initiatives
- Revenue recovery visible with TTM compounded sales growth of 10%, reversing the negative 3-year compounded sales growth of -4%
- 5-year compounded sales growth of 14% demonstrates the company's ability to grow its topline over a longer cycle despite near-term headwinds
- 5-year compounded profit growth of 36% reflects strong long-term earnings power even though recent years have seen a decline
- Stock is trading roughly 10% below its 52-week high of ₹4,958.9, suggesting it has held up well relative to its peak
- The stock has rallied approximately 53% from its 52-week low of ₹2,916.6 to ₹4,463.9, reflecting strong momentum off the bottom
- Trailing PE of 81.04x is extremely elevated for a chemicals company, leaving little room for earnings disappointment
- 3-year compounded profit growth of -24% signals a significant earnings decline over the medium term, which the premium valuation does not appear to reflect
- Return on equity of 7.25% (and a 3-year average of roughly 8%) is low, especially given the stock trades at 6.27x book value — the market is pricing in a much higher return profile than currently delivered
- TTM profit growth of 0% shows earnings have stagnated with no visible recovery yet, even as sales grew 10% in the same period
- Dividend yield of just 0.07% and a payout of only 6.44% of profits over the last three years offers negligible income to shareholders
- The company may be capitalizing interest costs, which could flatter reported profits and understate true borrowing expenses on the income statement
- 5-year average ROE of 13% has deteriorated sharply to 8% in the last year, indicating declining capital efficiency
- EPS of ₹55.08 against a share price of ₹4,463.9 underscores how much future growth is already priced in — any miss on execution could trigger a de-rating
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
TL;DR: Gujarat Fluorochemicals delivered strong Q2FY27 results with 32% EBITDA growth and improved return ratios, reflecting operational momentum. The ₹600 crore EV battery chemicals investment signals a strategic push into high-growth segments. No material headwinds surfaced in the latest update cycle. The trend is improving, though execution on the EV capex and sustaining margin expansion will be key to watch.
- EBITDA up 32% YoY Nov 03
Consolidated EBITDA rose 32% YoY to ₹473 crore in Q2FY27, with net profit expanding to ₹240 crore.
- ROCE improves to 17.17% Nov 03
Return on capital employed improved to 17.17% in H1FY27, while working capital days were reduced to 152 days, signalling better capital efficiency.
- ₹600Cr EV battery investment Nov 03
Company plans ₹600 crore investment in GFCL EV Products Limited to expand battery chemicals capacity, positioning for the EV supply chain.
Quarterly Results
₹ Cr| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,209 | 947 | 992 | 1,133 | 1,176 | 1,188 | 1,148 | 1,225 | 1,281 | 1,210 | 1,136 | 1,369 | 1,588 | 1,760 |
| Expenses | 861 | 783 | 786 | 895 | 914 | 893 | 854 | 919 | 937 | 846 | 861 | 1,062 | 1,162 | 1,287 |
| Operating Profit | 348 | 164 | 206 | 238 | 262 | 295 | 294 | 306 | 344 | 364 | 275 | 307 | 426 | 473 |
| OPM % | 29% | 17% | 21% | 21% | 22% | 25% | 26% | 25% | 27% | 30% | 24% | 22% | 27% | 27% |
| Other Income | 15 | 13 | 13 | 18 | 9 | 9 | 14 | 26 | 23 | 6 | −10 | 3 | 12 | 10 |
| Interest | 28 | 34 | 37 | 34 | 37 | 42 | 42 | 26 | 30 | 33 | 33 | 42 | 26 | 40 |
| Depreciation | 66 | 68 | 72 | 81 | 85 | 90 | 91 | 89 | 90 | 91 | 89 | 97 | 102 | 104 |
| PBT | 269 | 75 | 110 | 141 | 149 | 172 | 175 | 217 | 247 | 246 | 143 | 171 | 310 | 339 |
| Tax % | 25% | 29% | 27% | 28% | 28% | 30% | 28% | 12% | 26% | 27% | 29% | 42% | 29% | 29% |
| Net Profit | 201 | 53 | 80 | 101 | 108 | 121 | 126 | 191 | 182 | 179 | 102 | 100 | 219 | 240 |
| EPS (₹) | 18.3 | 4.82 | 7.28 | 9.19 | 9.83 | 11.02 | 11.47 | 17.39 | 16.57 | 16.29 | 9.29 | 9.38 | 20.12 | — |
Sep 2026: from the results filed on 3 Nov 2026, ahead of the full statement, so some rows are blank.
Profit & Loss
₹ Cr| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,851 | 2,729 | 2,606 | 2,650 | 3,954 | 5,685 | 4,281 | 4,737 | 4,996 | 5,303 |
| Expenses | 3,105 | 1,941 | 2,167 | 2,052 | 2,785 | 3,719 | 3,366 | 3,638 | 3,795 | 3,931 |
| Operating Profit | 745 | 788 | 439 | 598 | 1,168 | 1,965 | 915 | 1,100 | 1,201 | 1,372 |
| OPM % | 19% | 29% | 17% | 23% | 30% | 35% | 21% | 23% | 24% | 26% |
| Other Income | 112 | 78 | 190 | 199 | 161 | 172 | 100 | 115 | 111 | 11 |
| Interest | 279 | 56 | 105 | 113 | 78 | 117 | 133 | 147 | 138 | 134 |
| Depreciation | 299 | 164 | 192 | 202 | 205 | 236 | 286 | 355 | 367 | 379 |
| PBT | 279 | 645 | 332 | 482 | 1,045 | 1,785 | 595 | 713 | 807 | 870 |
| Tax % | 14% | −93% | 43% | 146% | 26% | 26% | 27% | 23% | 29% | — |
| Net Profit | 240 | 1,246 | 189 | −222 | 776 | 1,323 | 435 | 546 | 574 | 600 |
| EPS (₹) | — | — | 17.87 | −19.91 | 71.66 | 121 | 39.59 | 49.71 | 52.56 | 55.08 |
| Div. Payout % | 15% | 0% | 0% | 0% | 6% | 3% | 8% | 6% | 6% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 |
| Reserves | 4,756 | 3,499 | 3,705 | 3,482 | 4,244 | 5,510 | 5,925 | 7,242 | 7,855 |
| Borrowings | 2,000 | 968 | 1,718 | 1,591 | 1,556 | 1,515 | 2,096 | 2,080 | 2,721 |
| Other Liabilities | 2,986 | 441 | 634 | 885 | 1,067 | 1,335 | 1,201 | 1,270 | 1,273 |
| Total Liabilities | 9,753 | 4,919 | 6,067 | 5,969 | 6,878 | 8,371 | 9,233 | 10,602 | 11,859 |
| Fixed Assets | 3,813 | 2,305 | 2,414 | 2,367 | 2,514 | 3,111 | 4,264 | 4,285 | 4,822 |
| CWIP | 724 | 229 | 318 | 400 | 680 | 1,158 | 1,128 | 1,568 | 1,900 |
| Investments | 524 | 342 | 259 | 88 | 20 | 1 | 1 | 289 | 277 |
| Other Assets | 4,691 | 2,042 | 3,076 | 3,114 | 3,665 | 4,101 | 3,840 | 4,460 | 4,860 |
| Total Assets | 9,753 | 4,919 | 6,067 | 5,969 | 6,878 | 8,371 | 9,233 | 10,602 | 11,859 |
Cash Flow
₹ Cr| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Operating | 952 | 782 | 546 | 616 | 741 | 739 | 626 | 545 | 961 |
| Investing | 589 | −428 | −1,152 | −373 | −584 | −476 | −966 | −1,121 | −1,168 |
| Financing | −1,668 | 110 | 622 | −248 | −144 | −264 | 348 | 599 | 367 |
| Net Cash Flow | −127 | 464 | 17 | −5 | 14 | −2 | 7 | 24 | 160 |
| Free Cash Flow | −64 | 276 | −650 | 343 | 92 | 12 | −330 | −335 | −292 |
| CFO/OP | 157 | 101 | 136 | 80 | 83 | 62 | 90 | 67 | 101 |
Ratios
| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 184 | 77 | 79 | 92 | 72 | 71 | 72 | 92 | 94 |
| Inventory Days | 736 | 351 | 390 | 404 | 314 | 375 | 435 | 487 | 453 |
| Days Payable | 471 | 127 | 176 | 202 | 170 | 174 | 144 | 162 | 129 |
| Cash Conversion Cycle | 449 | 301 | 293 | 294 | 216 | 272 | 363 | 418 | 417 |
| Working Capital Days | 67 | 22 | 0 | 6 | 33 | 62 | 60 | 97 | 92 |
| ROCE % | — | 11% | 9% | 11% | 20% | 30% | 10% | 10% | 10% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Gujarat Fluorochemicals insights
63 extracted metrics across FY18–FY27.
Documents
- Q1 FY27 concall · Aug 2026Transcript PPT Recording
- Q4 FY26 concall · Jun 2026Transcript PPT Recording
- Q4 FY26 concall · May 2026PPT
- Q3 FY26 concall · Feb 2026Transcript PPT Recording
- Q2 FY26 concall · Nov 2025Transcript PPT Recording
- 26 Mar 2026
- 28 Jul 2025
- 26 Mar 2025
- 26 Dec 2024
- 1 Oct 2024
- General announcements 26 Oct 2026
Frequently Asked Questions about Gujarat Fluorochemicals
What does Gujarat Fluorochemicals Ltd do?
Where is Gujarat Fluorochemicals Ltd (FLUOROCHEM) listed?
Which sector does Gujarat Fluorochemicals Ltd belong to?
What is the PE ratio of Gujarat Fluorochemicals Ltd?
What is the 52-week high and low of Gujarat Fluorochemicals Ltd?
Does Gujarat Fluorochemicals Ltd pay dividends?
What is the Return on Equity (ROE) of Gujarat Fluorochemicals Ltd?
Company Information
Incorporated in 2018, Gujarat Fluorochemicals Limited, earlier known as Inox Fluorochemicals Limited, is a part of the INOX Group of Companies and has been demerged from GFL Ltd, into a separate legal entity. It is one of the leading producers of Fluoro-polymers, Fluoro-specialities, Chemicals and Refrigerants in India. It is one of the top five global players in the fluoropolymers market with exports to Europe, Americas, Japan and Asia.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/FLUOROCHEM.md for Gujarat Fluorochemicals Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.